Pill Identifier App

Data from Clinical Trial of MediGene's EndoTAGTM-1 in the Indication Pancreatic Cancer Will be Presented at ASCO Annual Meeting

MARTINSRIED/MUNICH, Germany, May 30, 2008-The biotech company MediGene AG (Frankfurt, Prime Standard:MDG) announced that on the occasion of the 44th annual congress of the American Society of Clinical Oncology (ASCO) safety and efficacy data obtained in the company's clinical phase II trial of EndoTAG(TM)-1 in the indication pancreatic cancer will be presented in a poster session. On June 2, the clinical trial's principal investigator, Prof. Löhr, Professor of Gastroenterology & Hepatology at Karolinska Institutet, Stockholm, and Head of Molecular Gastroenterology, German Cancer Research Center (DKFZ) Heidelberg, will explain the data. (8:00-12:00 local time, poster wall #43D in S Hall A1 at McCormick Place, Chicago, USA). In March, MediGene already published the major trial results, the detailed evaluation is expected in the fourth quarter of 2008.

EndoTAG(TM)-1: EndoTAG(TM)-1 consists of positively charged lipid complexes which transport the dissolved cytostatic drug paclitaxel systematically to the negatively charged endothelial cells of the newly formed tumor blood vessels. The drug is expected to attack the tumor blood vessels, simultaneously preventing the growth of new blood vessels. This should significantly reduce the nutrient supply of the tumor tissue, and stops further tumor growth. During the phase II trial in the indication pancreatic cancer the cytostatic drug Gemcitabine, which is directly targeted at the remaining tumor cells, was administered in combination with EndoTAG(TM)-1. In addition to the phase II trial in pancreatic cancer reported in this press release, MediGene is currently conducting a phase II trial of EndoTAG(TM)-1 for the treatment of hormone-resistant breast cancer, the results of which are expected in 2009. On the basis of MediGene's EndoTAG(TM) platform technology, the company is also investigating other therapeutic approaches using EndoTAG(TM).

This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the statements made herein. MediGene is not bound to update any of these forward-looking statements. EndoTAG(TM) and MediGene® are trademarks of MediGene AG

MediGene AG is a publicly quoted (Frankfurt, Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market, which are being distributed by partner companies. Another drug candidate has just received official recommendation for marketing authorization by the EMEA. MediGene is planning to start its own marketing activities. The company has several drug candidates in clinical development, including two products which each have an annual sales potential of more than one billion Euros per year. MediGene also has projects in research and pre-clinical development and possesses innovative platform technologies for the development of active ingredients. MediGene concentrates on researching, developing and commercializing novel drugs in three therapeutic areas: cancer, autoimmune diseases, and skin diseases.

Contact MediGene AG E-mail: investor@medigene.com Fax:++49 - 89 - 85 65 - 2920 Julia Hofmann / Dr. Georg Dönges, Public Relations, Tel.: ++49 - 89 - 85 65 - 3317 Dr. Michael Nettersheim / Dr. Georg Dönges, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946

 

Posted: May 2008

View comments

Hide
(web3)